Nasir Ahmad Chaudhry, et al
Oedema: The Role of Soluble Mediators. Br J
Ophthalmol. 2000; 84: 542-545.
Conflict of Interest
Authors declared no conflict of interest.
9. The Branch Vein Occlusion Study Group. Argon
laserphotocoagulation for macular edema in branch
vein occlusion. Am J Ophthalmol. 1984; 98: 271-282.
10. Raszewska-Steglinska M, Gozdek P, Cisiecki S,
Michalewska Z, Michalewski J, Nawrocki J.
Parsplana vitrectomy with ILM peeling for macular
edema secondaryto retinal vein occlusion. Eur J
Ophthalmol. 2009; 19: 1055-1062.
11. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced
chorioretinal venous anastomosis for non-ischemic
central or branch retinal vein occlusion. Arch
Ophthalmol. 1998; 116: 43-52.
12. Hahn P, Fekrat S. Best practices for treatment of
retinal vein occlusion. Curr Opin Ophthalmol. 2012; 23
(3): 175–181.
13. Haller JA, Bandello F, Belfort Jr R, Blumenkranz
MS, Gillies M, Heier J, et al. Ozurdexgeneva Study
Authors’ Designation and Contribution
Nasir Ahmad Chaudhry; Professor: Supervisor of this
project, study design, final manuscript review.
Sarmad Zahoor; Medical Officer: Data Collection and
analysis, Statistical work.
Usama Iqbal; Post Graduate Resident: Manuscript
writing and final review
Muhammad Owais Sharif; Senior Registrar: Data
Collection, Article review.
Muhammad Sharjeel; Assistant Professor: Data
collection and compiling, final review, Discussion
writing.
Group.
Randomized,
sham-controlled
trial
Asima Rafique; Post Graduate Resident: Data
Collection, Manuscript writing, final review
ofdexamethasone intravitreal implant in patients with
macularedema due to retinal vein occlusion.
Ophthalmology, 2010; 117: 1134-1146.
14. Park SP, Ahn JK. Changes of aqueous vascular
endothelialgrowth factor and interleukin-6 after
intravitreal triamcinolonefor branch retinal vein
occlusion. Clin Experiment Ophthalmol. 2008; 36: 831-
835.
15. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng
YS, Shima DT, et al. A therapeutic aptamer inhibits
angiogenesis by specifically targeting the heparin
binding domain of VEGF165. Proc Natl Acad Sci U
SA. 2005; 102: 18902-18907.
REFERENCES
1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang
JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY.
International Eye Disease Consortium: The prevalence
of retinal vein occlusion: pooled data from population
studiesfrom the United States, Europe, Asia, and
Australia. Ophthalmology, 2010; 117: 313–319.
2. Klein R, Moss SE, Meuer SM, Klein BE. The15-year
cumulative incidence of retinal vein occlusion: the
Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126:
513–518.
3. Hayreh SS, Zimmerman B, McCarthy MJ,
Podhajsky P. Systemic diseases associated with
various types of retinal occlusion. Am J Ophthalmol.
2001; 131: 61–77.
4. Cugati S, Wang JJ, Rochtchine E, Mitchell P. Ten-
year incidence ofretinal vein occlusion in an older
population: the Blue Mountain Eye study. Arch
Ophthalmol. 2006; 124: 726–732.
5. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors
for retinal vein occlusion. A case-control study.
Ophthalmology, 1992; 99: 509–514.
6. Aiello LP, Avery RL, Arrig PG, Keyt BA, Jampel
HD, Shah ST, et al. Vascular endothelial growthfactor
in ocular fluid of patients with diabetic retinopathy and
otherretinal disorders. N Engl J Med. 1994; 331: 1480–
1487.
16. Ferrara N, Damico L, Shams N, Lowman H, Kim R.
Development of ranibizumab, an anti-vascular
endothelial growth factor antigen binding fragment, as
therapy for neovascular age-related
macular
degeneration. Retina, 2006; 26: 859-870.
17. Ferrara N, Hillan KJ, Gerber HP, Novotny W.
Discovery and development of bevacizumab, an anti-
VEGF antibody for treating cancer. Nat Rev Drug
Discov. 2004; 3: 391-400.
18. Wroblewski JJ, Wells JA, Adamis AP, Buggage RR,
Cunningham ET, Goldbaum M, et al. Pegaptanib
sodium for macular edema secondary to central retinal
vein occlusion. Arch Ophthalmol. 2009; 127: 374-380.
19. Abegg M, Tappeiner C, Wolf-Schnurrbusch U,
Barthelmes D, Wolf S, Fleischhauer J. Treatment of
branch retinal vein occlusion induced macular edema
with bevacizumab. BMC Ophthalmology, 2008 Dec; 8
(1): 18.
20. Kornhauser T, Schwartz R, Goldstein M, Neudorfer
M, Loewenstein A, Barak A. Bevacizumab treatment
of macular edema in CRVO and BRVO: long-term
follow-up. (BERVOLT study: Bevacizumab for RVO
long-term follow-up). Graefe's Arch Clin Exp
7. Bringmann A, Reichenbach A, Wiedemann P.
Pathomechanisms of Cystoid Macular Edema.
Ophthalmic Res. 2004; 36: 241-249.
Doi: 10.1159/000081203.
8. Kent D, Vinores SA, Campochiaro PA. Macular
234
Pakistan Journal of Ophthalmology, 2020, Vol. 36 (3): 231-235